Phase 2
Completed N=118
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer
Her2 Negative Breast Cancer Patients
Source: ClinicalTrials.gov NCT01151046 ↗
Enrolled (actual)
118
Serious AEs
15.7%
Results posted
May 2016
Primary outcomePrimary: Progression Free Survival (PFS) — 15.9; 10.7 weeks
Summary
To determine whether the combination MM-121 + Exemestane in ER+ and/or PR+ breast cancer patients is more effective than Exemestane alone
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Progression Free Survival (PFS) |
15.9; 10.7 | — |
| SECONDARY Overall Survival |
NA; 96.3 | — |
Eligibility Criteria
Inclusion Criteria
- Locally advanced or metastatic breast cancer
- Histologically or cytologically confirmed ER+ and/or PgR+ and Her2 negative breast cancer
- ≥ 18 years of age
Exclusion Criteria
- Received prior treatment with exemestane
- Extensive visceral disease (rapidly progressive, life-threatening metastases, including symptomatic lymphangitic metastases)
- Symptomatic CNS disease
Data sourced from ClinicalTrials.gov (NCT01151046). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.